Market Overview:
The global genital herpes treatment market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of genital herpes, rising awareness about the disease, and technological advancements in the field of genitourinary medicine (GUM). The global genital herpes treatment market is segmented on the basis of type, application, and region. On the basis of type, it is divided into acyclovir, valacyclovir, famciclovir. On the basis of application, it is classified into HSV-1 and HSV-2 infections. Geographically, it is analyzed across North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (China Japan India South Korea Australia New Zealand), and Middle East & Africa (Saudi Arabia UAE Qatar South Africa). Some key players operating in this market are GlaxoSmithKline plc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co., Inc.
Product Definition:
Genital herpes treatment is a way to reduce the symptoms of genital herpes and the number of outbreaks. It may also help prevent transmission of the virus.
Acyclovir:
Acyclovir is a medication used for the treatment of genital herpes. It’s approved by the FDA to treat recurrent outbreaks in people with AIDS or those who have had extensive chickenpox. The drug has also been prescribed off-label to patients with genital herpes simplex virus 2 and 3 infections, but its main use is in the treatment of recurring outbreaks associated with these viruses.
The active ingredient was first identified and synthesized by Gilead Sciences Inc.
Valacyclovir:
Valacyclovir is an antiviral medication used for the treatment of genital herpes. It's approved by the FDA for both primary and secondary prevention of HSV infections. The drug has been studied to be effective in reducing viral shedding as well as incidence rates among individuals with HSV infection, thus making it a viable option for treating this condition.
Application Insights:
Based on application, the global market is segmented into herpes simplex virus type 1 (HSV-1) and HSV-2. The herpes simplex virus type 2 (HSV-2) segment dominated the overall market in terms of revenue in 2017. Increasing awareness about genital herpes is one of the major factors contributing to its increasing prevalence and incidence rates. According to a study published by CDC, it was estimated that around 60 million people were affected by HSV-2 in 2015 worldwide. Moreover, an increase in condomless sex among individuals due to rising cases of HIV/AIDS has also increased the risk of transmission from person to person through cracks or sores caused inside the vagina or anus which results in infection with HSV thus driving demand for effective treatment options such as acyclovir and valacyclovir over recent years globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key manufacturers, such as Merck & Co., Inc.; F. Hoffmann-La Roche AG; and Genentech, Inc., which are engaged in developing novel drugs for genital herpes treatment. Moreover, increasing awareness about these diseases is also driving growth in this region. For instance, according to a survey conducted by National STD/AIDS Hotline Network (NHSAN), around 44% of Americans were aware about genital HSV-2 infection while 32% knew that they could get HIV from oral sex partners with an active virus infection.
Asia Pacific is expected to witness lucrative CAGR over the forecast period owing to rising prevalence of sexually transmitted infections (STIs) among people aged 15-24 years and 25-34 years across countries like India.
Growth Factors:
- Increasing incidence of genital herpes infections
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective treatments for genital herpes
- Availability of new and innovative therapies for the treatment of genital herpes
- Growing number of clinical studies on new therapies for the treatment of genital herpes
Scope Of The Report
Report Attributes
Report Details
Report Title
Genital Herpes Treatment Market Research Report
By Type
Acyclovir, Valacyclovir, Famciclovir
By Application
HSV-1, HSV-2
By Companies
Teva, Abbott, Sun, Mylan, Pfizer, GlaxoSmithKline, Dr. Reddy's, Novartis, Valeant
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
220
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Genital Herpes Treatment Market Report Segments:
The global Genital Herpes Treatment market is segmented on the basis of:
Types
Acyclovir, Valacyclovir, Famciclovir
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
HSV-1, HSV-2
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Abbott
- Sun
- Mylan
- Pfizer
- GlaxoSmithKline
- Dr. Reddy's
- Novartis
- Valeant
Highlights of The Genital Herpes Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Acyclovir
- Valacyclovir
- Famciclovir
- By Application:
- HSV-1
- HSV-2
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genital Herpes Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for genital herpes, but there are treatments available that can help manage the symptoms. Treatment options include antiviral medications, topical creams and gels, and oral suppressive therapy. Some people may also need to take daily medication for life to prevent outbreaks.
Some of the key players operating in the genital herpes treatment market are Teva, Abbott, Sun, Mylan, Pfizer, GlaxoSmithKline, Dr. Reddy's, Novartis, Valeant.
The genital herpes treatment market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genital Herpes Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genital Herpes Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genital Herpes Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genital Herpes Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genital Herpes Treatment Market Size & Forecast, 2020-2028
4.5.1 Genital Herpes Treatment Market Size and Y-o-Y Growth
4.5.2 Genital Herpes Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Acyclovir
5.2.2 Valacyclovir
5.2.3 Famciclovir
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 HSV-1
6.2.2 HSV-2
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Genital Herpes Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Genital Herpes Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Acyclovir
9.6.2 Valacyclovir
9.6.3 Famciclovir
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 HSV-1
9.10.2 HSV-2
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Acyclovir
10.6.2 Valacyclovir
10.6.3 Famciclovir
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 HSV-1
10.10.2 HSV-2
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Acyclovir
11.6.2 Valacyclovir
11.6.3 Famciclovir
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 HSV-1
11.10.2 HSV-2
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Acyclovir
12.6.2 Valacyclovir
12.6.3 Famciclovir
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 HSV-1
12.10.2 HSV-2
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Acyclovir
13.6.2 Valacyclovir
13.6.3 Famciclovir
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 HSV-1
13.10.2 HSV-2
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Genital Herpes Treatment Market: Competitive Dashboard
14.2 Global Genital Herpes Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Abbott
14.3.3 Sun
14.3.4 Mylan
14.3.5 Pfizer
14.3.6 GlaxoSmithKline
14.3.7 Dr. Reddy's
14.3.8 Novartis
14.3.9 Valeant
